Moderna, Inc. Common Stock
MRNA XNAS
$51.34
+0.42 (+0.82%)
▲
15-min delayed
Open
$50.44
High
$52.68
Low
$50.34
Volume
4.81M
Market Cap
$20.34B
About Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| TTM 2025 | $1.94B | $-2,822,000,000 | $-7.26 |
| FY 2025 | $1.94B | $-2,822,000,000 | $-7.26 |
| Q3 2025 | $1.02B | $-200,000,000 | $-0.51 |
| Q2 2025 | $142.00M | $-825,000,000 | $-2.13 |
TickerDaily Coverage
Why Are These 5 Stocks Moving Biggest Before the Bell Today? Pre-Market Movers
Market News
Sarah Mitchell · Mar 11, 2026
Five major stocks are making significant pre-market moves ahead of the opening bell, driven by...
Why Are These Stocks Moving Before Market Open? Top 5 Pre-Market Movers Today
Market News
Sarah Mitchell · Mar 9, 2026
Five major stocks are trading sharply higher and lower in pre-market action ahead of the opening...
View All Coverage →
Get MRNA Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Moderna, Inc. Common Stock.
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.